Kura Oncology to report Q1 2026 financial results on May 12 with a webcast and call.

Kura Oncology, a biopharmaceutical company focused on precision cancer medicines, announced it will release its first quarter 2026 financial results on May 12, 2026, after U.S. market close. The company will host a webcast and conference call to discuss the results and provide a corporate update. Kura Oncology is known for its FDA-approved drug KOMZIFTI™ for acute myeloid leukemia and continues advancing cancer treatments. Investors can access the webcast via the company’s website.